FDA panel backs Vysis' test for aggressive breast cancers
This article was originally published in Clinica
Executive Summary
An FDA advisory panel has unanimously recommended approval be given to a gene-based test that can identify whether a breast cancer patient has a more aggressive and deadly form of the disease. The recommendation is subject to certain conditions relating to labelling.